Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

PHASE3CompletedINTERVENTIONAL

Enrollment

324

Participants

Timeline

Start Date

October 20, 2018

Primary Completion Date

November 1, 2024

Study Completion Date

March 1, 2025

Conditions

Pancreatic Adenocarcinoma ResectableNeoadjuvant Chemotherapy

Interventions

DRUG

AG regimen

Combination of Nab-paclitaxel 125 mg/m\^2 and Gemcitabine 1000 mg/m\^2

DRUG

mFolfirinox

Folic acid 400mg/m\^2, 5- fluorouracil 2400mg/m\^2 for 46h, irinotecan 135mg/m\^2 and oxaliplatin 68mg/m\^2

Trial Locations (1)

The second affiliated hospital of Zhejiang University, Hangzhou

All Listed Sponsors

lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER

NCT03750669 - Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer | Biotech Hunter | Biotech Hunter